Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2016

View Archived Issues

DNAAF1 mutation contributes to testicular cancer susceptibility

BMS, Calithera Biosciences to evaluate CB-839 plus nivolumab

First patients enrolled in phase IIa study of MS-1819-SD

BioInvent and Pfizer sign cancer immunotherapy research collaboration and license agreement

Triphase Accelerator and Celgene enter new collaboration

Sunovion obtains license to three approved COPD products from Novartis

Takeda decides to include Japan and Canada in Cx-601 agreement with TiGenix

Concert Pharmaceuticals begins phase II study of CTP-656

Phase II/III topline data on Soliris to prevent delayed graft function after kidney transplantation

Lexicon Pharmaceuticals' inTandem2 phase III study of sotagliflozin meets primary endpoint

Discovery of novel pH transistor nanoprobe for cancer specific detection of malignant tumours

Binding to intracellular side of CCR9 receptor exerts antagonistic effect

Ionis Pharmaceuticals earns news milestone payment in Janssen Biotech collaboration

Dermavant Sciences enters agreement with Portola for cerdulatinib

Sumitomo Dainippon Pharma to acquire Tolero Pharmaceuticals

Sun Pharma to acquire Odomzo for global markets

Eisai and Keio University enter new joint research agreement

Avastin receives orphan drug designation in Japan

PharmaMar enters agreement with Chugai for PM-1183

GemVax & KAEL patent TNF-alpha production inhibitors and TGF-beta inhibitors

Incyte and Merus collaborate on bispecific antibodies

Chiesi Farmaceutici develops PDE4B inhibitors and/or muscarinic M3 receptor antagonists

Pfizer completes acquisition of AstraZeneca's small molecule anti-infective business

Bristol-Myers Squibb presents apelin receptor agonists

European Commission grants orphan drug designation to AM-0010 for pancreatic cancer

First-in-class cytotoxic drug conjugate shows great potential against multiple tumor types in vivo

Vectura signs development and license agreement with Mundipharma for VR-2076

Novelion Therapeutics announces submission of MAA for metreleptin in E.U.

Helix BioPharma, ProMab Biotechnologies to establish CAR-T therapy collaboration

Vifor Pharma and ChemoCentryx expand kidney health alliance

DMC recommends continuation of phase III trial of Progenics' 1404

Benitec Biopharma announces progress in ddRNAi program for HBV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...